THURSDAY, June 5, 2025 (HealthDay News) -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leuco
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

62 0
THURSDAY, June 5, 2025 (HealthDay News) -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leuco